You are here: Industry Insights > JHL Biotech

News List

JHL Biotech receives China approval for cancer Biosimilar biospectrumasia
October 19, 2018
The proposed bevacizumab biosimilar, JHL1149, treats several forms of cancer, including advanced non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic kidney cancer, advanced cervical cancer and recurrent ovarian cancer
JHL Biotech Gets Positive CHMP Scientific Advice for Bevacizumab Biosimilar biospectrumasia
August 13, 2018
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
JHL Biotech raises $106M in pre-IPO funding biospectrumasia
May 31, 2018
JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio.
JHL Biotech submits application for Bevacizumab Biosimilar biospectrumasia
April 18, 2018
Once approved, JHL1149 will be manufactured at JHL's facility in Wuhan, China
JHL Biotech Shareholders Vote to Voluntarily Delist from China's Taiwan, China Region Exchange prnasia
February 02, 2018
JHL Biotech (TPEx: 6540) announced that its shareholders voted to voluntarily delist the company's ordinary shares from the Emerging Stock Market of the Taipei Exchange (TPEx).
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Trea prnasia
December 21, 2017
JHL Biotech Inc. (Stock Code: 6540.TWO) announced that it submitted a Phase I Clinical Trial Application on December 15, 2017 to European authorities (Bulgarian Drug Agency) for its proposed bevacizumab biosimilar, JHL1149.
M&As this week: JHL Biotech, Bio Techne, Metabolon pharmaceufical-technology
September 08, 2017
JHL Biotech has acquired 40% stake in a biomedical company based in Wuhan, China, in a long-term investment pursuit.